Romero-Calle Danitza, Guimarães Benevides Raquel, Góes-Neto Aristóteles, Billington Craig
Postgraduate Program in Biotechnology, State University of Feira de Santana (UEFS), Av. Transnordestina S/N, Feira de Santana-BA 44036-900, Brazil.
Health & Environment Group, Institute of Environmental Sciences and Research, PO Box 29-181, Christchurch 8540, New Zealand.
Antibiotics (Basel). 2019 Sep 4;8(3):138. doi: 10.3390/antibiotics8030138.
Antimicrobial resistance is increasing despite new treatments being employed. With a decrease in the discovery rate of novel antibiotics, this threatens to take humankind back to a "pre-antibiotic era" of clinical care. Bacteriophages (phages) are one of the most promising alternatives to antibiotics for clinical use. Although more than a century of mostly ad-hoc phage therapy has involved substantial clinical experimentation, a lack of both regulatory guidance standards and effective execution of clinical trials has meant that therapy for infectious bacterial diseases has yet to be widely adopted. However, several recent case studies and clinical trials show promise in addressing these concerns. With the antibiotic resistance crisis and urgent search for alternative clinical treatments for bacterial infections, phage therapy may soon fulfill its long-held promise. This review reports on the applications of phage therapy for various infectious diseases, phage pharmacology, immunological responses to phages, legal concerns, and the potential benefits and disadvantages of this novel treatment.
尽管采用了新的治疗方法，但抗菌耐药性仍在增加。随着新型抗生素发现率的下降，这有可能使人类回到临床护理的“抗生素前时代”。噬菌体是临床上最有前途的抗生素替代品之一。尽管一个多世纪以来，大多是临时的噬菌体疗法涉及大量临床实验，但缺乏监管指导标准和临床试验的有效执行意味着细菌性传染病的治疗尚未得到广泛采用。然而，最近的几项案例研究和临床试验显示出解决这些问题的希望。随着抗生素耐药性危机以及对细菌感染替代临床治疗方法的迫切探索，噬菌体疗法可能很快实现其长期以来的前景。本综述报告了噬菌体疗法在各种传染病中的应用、噬菌体药理学、对噬菌体的免疫反应、法律问题以及这种新型治疗方法的潜在利弊。
